TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:33
NEOGENOMICS INC ( NEO ) https://www.neogenomics.com
20.55USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
NEO
124.10%
SPY
30.72%
-62.91%
NEO
SPY
112.82%
NEO
82.83%
SPY
201.04%
NEO
470.83%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2582.87
3098.76
0.86
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-26.81
4.49
2.73
-2.51
0.00
-94.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-15.92
41.01
-5.73
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.8694
-6.99
-6.33
1.21
Other Earnings and Cash Flow Stats:
NEOGENOMICS INC ( NEO ) Net Income TTM ($MM) is -108.85
NEOGENOMICS INC ( NEO ) Operating Income TTM ($MM) is -118.94
NEOGENOMICS INC ( NEO ) Owners' Earnings Annual ($MM) is 0.00
NEOGENOMICS INC ( NEO ) Current Price to Owners' Earnings ratio is 0.00
NEOGENOMICS INC ( NEO ) EBITDA TTM ($MM) is -43.31
NEOGENOMICS INC ( NEO ) EBITDA Margin is -5.73%
Capital Allocation:
NEOGENOMICS INC ( NEO ) has paid 0.00 dividends per share and bought back -1.262 million shares in the past 12 months
NEOGENOMICS INC ( NEO ) has reduced its debt by 6.1579999999999 million USD in the last 12 months
Capital Structure:
NEOGENOMICS INC ( NEO ) Interest-bearing Debt ($MM) as of last quarter is 611
NEOGENOMICS INC ( NEO ) Annual Working Capital Investments ($MM) are -281
NEOGENOMICS INC ( NEO ) Book Value ($MM) as of last quarter is 947
NEOGENOMICS INC ( NEO ) Debt/Capital as of last quarter is 64%
Other Balance Sheet Stats:
NEOGENOMICS INC ( NEO ) has 306 million in cash on hand as of last quarter
NEOGENOMICS INC ( NEO ) has 92 million of liabilities due within 12 months, and long term debt 537 as of last quarter
NEOGENOMICS INC ( NEO ) has 125 common shares outstanding as of last quarter
NEOGENOMICS INC ( NEO ) has 0 million USD of preferred stock value
Academic Scores:
NEOGENOMICS INC ( NEO ) Altman Z-Score is 2.41 as of last quarter
NEOGENOMICS INC ( NEO ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
NEOGENOMICS INC ( NEO ) largest shareholder is Geode Capital Management, LLC owning 2706214 shares at 55.61 ($MM) value
Alicia C Olivo(an insider) Sold 2669 shares of NEOGENOMICS INC ( NEO ) for the amount of $49082.91 on 2023-11-17
1.42% of NEOGENOMICS INC ( NEO ) is held by insiders, and 93.40% is held by institutions
NEOGENOMICS INC ( NEO ) went public on 1999-11-02
Other NEOGENOMICS INC ( NEO ) financial metrics:
FCF:-64.72
Unlevered Free Cash Flow:0.00
EPS:-0.59
Operating Margin:-15.92
Gross Profit Margin:41.01
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-7.82
Beta:1.21
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About NEOGENOMICS INC ( NEO ) :
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.